# US 2021/0231690 A1 · In vitro method, use of an agent and collection device for the inhibition of coagulation in blood

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0231690 A1
- Document ID: US20210231690A1
- Status: Published application
- Kind: A1
- Application number: 17/164,080
- Filed: 2021-02-01
- Published: 2021-07-29
- Earliest claimed: 2013-02-28
- Assignees: Petra Weser-Bisse
- Inventors: Emmanuel Bisse
- Web page: https://patentgrep.com/patent/US20210231690A1

## CPC

- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- A61B 5/15003: {for venous or arterial blood}
- A61B 5/150343: {Collection vessels for collecting blood samples from the skin surface, e.g. test tubes, cuvettes (sampling from within body cavities A61B5/150015, A61B5/150045)}
- A61B 5/150755: {Blood sample preparation for further analysis, e.g. by separating blood components or by mixing}
- A61B 5/150992: {Blood sampling from a fluid line external to a patient, such as a catheter line, combined with an infusion line; Blood sampling from indwelling needle sets, e.g. sealable ports, luer couplings or valves}
- A61B 5/153: {Devices} specially adapted for taking samples of venous or arterial blood, e.g. with syringes
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

The present invention relates to a method and a use of an agent for the in vitro inhibition of coagulation in blood and a blood collection device provided for said method and use.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method for collecting and analysing and optionally storing blood in vitro, comprising:
providing a blood collection device,
mixing blood after its withdrawal in said blood collection device with an anticoagulant substance as the only anticoagulant, wherein said anticoagulant substance is provided as a free acid having a pKa of >0.9 and is selected from the group consisting of ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, citric acid, tricarballylic acid, benzenepentacarboxylic acid, mellitic acid, and tetrahydrofuran-2,3,4,5-tetracarboxylic acid or mixtures thereof, wherein the concentration of said anticoagulant substance provided as free acid having a PKa of >0.9 is at least 0.1 mmol/L of blood mixed therewith,
wherein said mixing is carried out under conditions that in the anticoagulant acid substance as provided, all of the carboxyl groups in the molecule are protonated,
wherein coagulation in blood is thereby inhibited.

### Claim 17 (depends on 16)

The method according to claim 16, wherein said anticoagulant substance is:
(i) provided as free acid having a pKa of >0.9; or
(ii) provided as free acid having a pKa of >0.9 dissolved in a solvent.

### Claim 18 (depends on 17)

The method according to claim 17, wherein in case (ii) the solvent is selected from the group consisting of an aqueous solution, water, and alcohol and mixtures of water and alcohol.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the blood, collected in a single device and mixed with said anticoagulant substance and optionally after being stored in the blood collection device for a desired period of time, is subsequently subjected to at least one test for the determination of at least one blood component.

### Claim 20 (depends on 16)

The method according to claim 16, wherein the blood, collected in a single device and mixed with said anticoagulant substance and optionally after being stored in the blood collection device for a desired period of time, is subsequently subjected to at least one test for the determination of at least one blood component and further to multiple tests comprising at least one hematologic test, at least one coagulation test and at least one further clinical chemistry analysis.
